Evidence map›Paper›PMID 21620888›Full record

ReviewPharmacology & therapeutics2011

The interaction between HCV and nuclear receptor-mediated pathways.

Zoe Raglow, Carly Thoma-Perry, Richard Gilroy, Yu-Jui Yvonne Wan

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. SOCS proteins in infectious diseases of mammals.Veterinary immunology and immunopathology · 2013
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zoe RaglowDepartment of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Carly Thoma-Perry
Richard Gilroy
Yu-Jui Yvonne Wan
University of Kansas · US

Funding

Retinoids Xenobiotic Metabolism and Tumor PromotionR01CA053596 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WAN, YU-JUI YVONNE · 1996 to 2014
$4.5M
RETINOIC ACID RECEPTOR ALPHA-FETOPROTEIN AND HEPATOMAR29CA053596 · NCI · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI WAN, YU-JUI YVONNE · 1991 to 1995
–
NCI NIH HHS CA 53596NCI NIH HHS R01 CA053596
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is presently the leading indication for liver transplantation in Western countries. Treatment for HCV infection includes a combination of pegylated interferon and ribavirin, which produces highly variable response rates. This reflects the lack of information regarding the roles of host and viral components during viral pathogenesis. Vital processes regulated by the liver, including metabolism, lipid homeostasis, cellular proliferation, and the immune response, are known to be systematically dysregulated as a result of persistent HCV infection. Nuclear receptors and their ligands are recognized as indispensable regulators of liver homeostasis. Pathways mediated by the nuclear receptor superfamily have been shown to be profoundly disrupted during HCV infection, leading to an increased importance in elucidating the exact nature of this complex relationship. Expanded understanding of the role of nuclear receptors in HCV infection may therefore be an essential step in the search for a more universally effective treatment.

Indexed as

Molecular Targeted TherapyAnimalsAntiviral AgentsHepacivirusHepatitis C, ChronicHumansLiverLiver TransplantationReceptors, Cytoplasmic and NuclearAntiviral AgentsReceptors, Cytoplasmic and Nuclear

Identifiers

PMID21620888
PMCPMC3152951
OpenAlexW2048338928

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.